TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(3) Registration No. 333-261185 PROSPECTUS ...
false000074859200007485922021-11-232021-11-23 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C...
TABLE OF CONTENTS As filed with the Securities and Exchange Commission on November 18, 2021. Registration No...
November 18, 2021 VIA EDGAR Securities and Exchange Commission Division of Corporation...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A/A (Amendment No...
false12-312021Q300007485920.50.500007485922021-01-012021-09-3000007485922021-11-0800007485922020-12...
NEW YORK, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq:BTX) (“Brooklyn”), a...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 25 NOTIFICAT...
false0000748592NYSEAMER00007485922021-10-132021-10-13 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington...
NEW YORK, Oct. 14, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX...
As filed with the Securities and Exchange Commission on October 12, 2021. Registration No. 333- UNITED STATES SECURITIES AND...
trueAmendment No. 10000748592NYSEAMER00007485922021-07-162021-07-16 UNITED STATES SECURITIES AND EXCHANGE...
false12-31Brooklyn ImmunoTherapeutics, Inc.DE140 58TH STREET, BUILDING ASUITE 2100BROOKLYNNY0000748592NYSEAMER00007485922021-09-202021-09-20...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.